Partial plasma cell differentiation as a mechanism of lost major histocompatibility complex class II expression in diffuse large B-cell lymphoma
about
Lymphoma: immune evasion strategiesHLA dependent immune escape mechanisms in B-cell lymphomas: Implications for immune checkpoint inhibitor therapy?The significance of FOXP1 in diffuse large B-cell lymphoma.Manifestations of gastrointestinal plasmablastic lymphoma: a case series with literature reviewGenetic lesions in diffuse large B-cell lymphomasHLA specificities are associated with prognosis in IGHV-mutated CLL-like high-count monoclonal B cell lymphocytosis.Lack and/or aberrant localization of major histocompatibility class II (MHCII) protein in plasmablastic lymphomaFOXP1 suppresses immune response signatures and MHC class II expression in activated B-cell-like diffuse large B-cell lymphomas.FOXP2-positive diffuse large B-cell lymphomas exhibit a poor response to R-CHOP therapy and distinct biological signatures.Vitamin D Receptor Expression in Plasmablastic Lymphoma and Myeloma Cells Confers Susceptibility to Vitamin D.Histone deacetylase inhibitors activate CIITA and MHC class II antigen expression in diffuse large B-cell lymphoma.Prognostic significance of HLA class I and II expression in patients with diffuse large B cell lymphoma treated with standard chemoimmunotherapy.HLA-G and MHC Class II Protein Expression in Diffuse Large B-Cell Lymphoma.A phase II study of belinostat (PXD101) in relapsed and refractory aggressive B-cell lymphomas: SWOG S0520.T cell inhibitory mechanisms in a model of aggressive Non-Hodgkin's Lymphoma.A Phase I/II Trial of Vorinostat (SAHA) in Combination with Rituximab-CHOP in Patients with Newly Diagnosed Advanced Stage Diffuse Large B-Cell Lymphoma (DLBCL): SWOG S0806.Aberrant cytoplasmic expression of MHCII confers worse progression free survival in diffuse large B-cell lymphoma.Human leukocyte antigen-DR expression on flow cytometry and tumor-associated macrophages in diffuse large B-cell lymphoma treated by rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone therapy: retrospective cohort study
P2860
Q28080705-D14BE0CE-F21C-446A-9AF1-F17EC3445EA3Q33632104-D0849ED0-3F7C-4173-9C64-AA75D50FEEC8Q34047455-E6AE9EB1-C11B-4777-AB22-509F558904A1Q34137455-8054071C-1CC4-47D3-AAD5-A83BF474B24FQ35974341-4023573A-C221-4FFF-9806-BB976600FC0CQ36294042-45B02EE9-D1EE-4F00-A9B1-86EFD2D85459Q36366994-6C6E18C0-FB34-4F1D-9832-36FA2E81ECF0Q36650112-63317C96-1824-4786-8177-A8B928DCA415Q37619689-195B4930-C611-47C2-B3DE-7D157E49035CQ38724993-400B872C-51B9-4D8D-9997-55754036AD46Q39136897-5D0E09F7-579C-42F5-895F-DE173E9E3B10Q39492021-F80F9C72-090E-4751-9261-935588F4DA90Q41050317-A7A6ACA3-7A5C-4496-AD89-2FBA882E3D21Q41652576-32C00B9E-4437-40B6-97E4-FD233598AEC3Q47217197-EA196234-5B48-4C6C-A5A6-76BA78F9BFA7Q47562297-A126F85E-C51A-448D-B353-5C35F4C53D31Q48197020-D4216702-C64C-4911-931E-D84A260575D2Q57917353-A79AA4A1-8577-4515-9B13-546F49EE5ECE
P2860
Partial plasma cell differentiation as a mechanism of lost major histocompatibility complex class II expression in diffuse large B-cell lymphoma
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Partial plasma cell differenti ...... diffuse large B-cell lymphoma
@ast
Partial plasma cell differenti ...... diffuse large B-cell lymphoma
@en
type
label
Partial plasma cell differenti ...... diffuse large B-cell lymphoma
@ast
Partial plasma cell differenti ...... diffuse large B-cell lymphoma
@en
prefLabel
Partial plasma cell differenti ...... diffuse large B-cell lymphoma
@ast
Partial plasma cell differenti ...... diffuse large B-cell lymphoma
@en
P2093
P2860
P1433
P1476
Partial plasma cell differenti ...... diffuse large B-cell lymphoma
@en
P2093
Betty J Glinsmann-Gibson
Diane R Fernandez
Karl E Garsha
Kristie A Vanpatten
Lisa M Rimsza
Patrick Brunhoeber
Sarah T Wilkinson
Thomas M Grogan
P2860
P304
P356
10.1182/BLOOD-2011-07-363820
P407
P577
2011-12-13T00:00:00Z